Trial NCT04366206
Publication Rossi B, medRxiv, 2020
| Methods | |
| Non-randomized study | |
| Location :
Single center / France Follow-up duration (days): 28 | |
| Inclusion criteria | Inclusion criteria was severe COVID-19 pneumonia, i.e. pulse oxygen (O2) saturation (SpO2) <=96% despite 79 O2 flow>=6 L/minute delivered by high concentration oxygen mask, for >6 hours. |
| Exclusion criteria | excluded patients under invasive mechanical ventilation and those critical care medicine department. |
| Type of analysis | Propensity score matching |
| Interventions | |
| Treatment
Tocilizumab (400mg) Co-Intervention: Standard care |
|
| Control
Standard care Definition of Standard care: * | |
| Participants | |
| N analyzed 168 participants (n1=84 / n2= 84) | |
| Characteristics of participants N=168 Mean age : 64.6 104 males Severity : Mild: n=0 / Moderate: n=0/ Severe: n=168 Critical: n=0 | |
| Primary outcome | |
| In the register NR | |
| In the report composite of mortality and ventilation, with a maximum follow-up of 28 days. | |
| Documents avalaible |
Protocol NR Statistical plan NR Data-sharing stated No |
| Risk of bias Overall The overall risk of bias reported in the table corresponds to the highest risk of bias for the outcomes assessed for the systematic review |
Moderate |
| Notes | * |